Clinical Trial

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.
Protocol Amendment History 3 changes
notable Trial sites expanded: 10 -> 14 locations 2026-08-12
notable Trial sites expanded: 2 -> 10 locations 2026-07-16
critical Recruitment opened 2026-05-13
Trial Details
NCT Number NCT07479797
Lead Sponsor Kite, A Gilead Company
Conditions Relapsed or Refractory Large B-cell Lymphoma
Enrollment 550 participants
Start Date 2026-05-22
Primary Completion 2031-05 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-11